The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Theo de WitteDuring the EHA 2022 Congress, the MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, How do we differentiate high-risk MDS from AML?
How do we differentiate high-risk MDS from AML?
De Witte begins by explaining the implications of the new International Prognostic Scoring System (IPSS) for MDS, and the flaws of existing risk-based scoring systems. De Witte then discusses the data from the patient cohort used to develop the new IPSS, including the most relevant genetic predictors of adverse and favorable outcomes. De Witte also talks about the parameters that can be given by the IPSS calculator.